X0206 3 2021-01-28 0 0001454789 CATABASIS PHARMACEUTICALS INC CATB 0001843393 Callori Fred C/O CATABASIS PHARMACEUTICALS, INC. 100 HIGH STREET, FLOOR 28 BOSTON MA 02110 1 0 0 0 Common Stock 543373 I By Xontogeny, LLC Common Stock 1933551 I By Perceptive Xontogeny Venture Fund, LP Series X Convertible Preferred Stock Common Stock 8234 I By Xontogeny, LLC Series X Convertible Preferred Stock Common Stock 29303 I By Perceptive Xontogeny Venture Fund, LP On January 28, 2021, Issuer completed its merger with Quellis Biosciences, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated January 28, 2021. In connection with the Merger, a limited partnership and a limited liability company (together, the "Funds") in which the Reporting Person has an indirect pecuniary interest received shares of Issuer common stock and shares of Series X Convertible Preferred Stock in exchange for an aggregate of 350,000 shares of Quellis Biosciences, Inc. common stock and 1,245,447 shares of Quellis Biosciences, Inc. preferred stock. The Reporting Person disclaims beneficial ownership of the securities held by the Funds, except to the extent of his pecuniary interest therein. Upon stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of common stock, each share of Series X Non-Voting Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations. Exhibit 24 - Power of Attorney. /s/ Benjamin Harshbarger, attorney-in-fact for Frederick P. Callori 2021-02-01